ThermoGenesisHoldingsInc . (NASDAQ:THMO) shares were up 12.4% during mid-day trading on Tuesday . The company traded as high as $4.74 and last traded at $4.43, approximately 288,300 shares changed hands during trading. An increase of 345% from the average daily volume of 64,852 shares. The stock had previously closed at $3.94.

Several research firms have recently issued reports on THMO. ValuEngine upgraded shares of ThermoGenesisHoldingsInc . from a “hold” rating to a “buy” rating in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $7.50 target price on shares of ThermoGenesisHoldingsInc . in a report on Thursday, November 21st.

The company has a quick ratio of 1.36, a current ratio of 1.96 and a debt-to-equity ratio of 1.16. The stock has a market capitalization of $11.74 million, a price-to-earnings ratio of -1.23 and a beta of 1.02. The business has a 50-day moving average price of $3.43.

ThermoGenesisHoldingsInc . (NASDAQ:THMO) last posted its earnings results on Tuesday, November 19th. The company reported ($0.78) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.66). The firm had revenue of $4.06 million for the quarter, compared to the consensus estimate of $4.80 million. ThermoGenesisHoldingsInc . had a negative return on equity of 87.88% and a negative net margin of 89.98%. As a group, sell-side analysts forecast that ThermoGenesisHoldingsInc . will post -0.16 earnings per share for the current fiscal year.

About ThermoGenesisHoldingsInc . (NASDAQ:THMO)

ThermoGenesis Holdings, Inc develops, commercializes, and markets a range of automated technologies for cell-based therapies in the United States, China, rest of Asia, Europe, and internationally. The company operates through two segments, Clinical Development and Device. It offers AutoXpress System, an automated system for the isolation, collection and storage of hematopoietic stem cell concentrates derived from cord blood and peripheral blood; Point-of CareXpress System for the rapid, automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells; CAR-TXpress System that addresses the critical unmet need for chemistry, manufacturing and controls improvement of the emerging CAR-T therapies for cancer patients; BioArchive Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for stem cell samples and clinical products; and manual disposables.

See Also: How is the discount rate different from the Federal Funds rate?

Receive News & Ratings for ThermoGenesisHoldingsInc . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ThermoGenesisHoldingsInc . and related companies with's FREE daily email newsletter.